Switching Between Reference Adalimumab and Biosimilars in Adult Patients With Inflammatory Bowel Disease: A Systematic Literature Review. - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/42465156
Review indicates similar remission and safety profiles between reference and biosimilar adalimumab in IBD patients; persistence varies, immunogenicity data limited.
Switching shows comparable remission and safety; persistence outcomes vary, and immunogenicity data are limited.
Strengthening Pharmacovigilance in Latin America: Multidisciplinary Insights from Two ISoP Latin American Chapter Symposia. - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/41863709
Discover ISoP LATAM's approach to pharmacovigilance in Latin America, highlighting regulation, education, and AI integration from symposia in Cartagena and Merida.
ISoP LATAM symposia in Cartagena (2023) and Merida (2025) focus on regulatory harmonization, biosimilar monitoring, pharmacovigilance education, and AI integration.
EULAR recommendations for the management of rheumatoid arthritis with synthetic and biologic disease-modifying antirheumatic drugs: 2025 update. - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/41826212
Explore the 2025 EULAR recommendations for managing rheumatoid arthritis, focusing on DMARDs' safety, efficacy, and specific treatment strategies.
Updated EULAR guidelines for RA management emphasize DMARDs' efficacy, safety, and cost, detailing conventional synthetic, biological, and targeted synthetic DMARDs, and strategies like treat-to-target.
Safety and efficacy of biosimilar aflibercept MYL-1701P in diabetic macular oedema: 20-week extension results following the INSIGHT pivotal trial. - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/42373197
Explore the safety and efficacy of biosimilar aflibercept MYL-1701P in diabetic macular oedema over a 20-week extension, showing similar outcomes to reference aflibercept, despite study limitations.
Biosimilar aflibercept MYL-1701P showed comparable safety and efficacy to reference aflibercept in diabetic macular oedema patients during a 20-week extension study, despite limitations like small participant number.
Observational study of trastuzumab biosimilar in patients with HER2-positive breast cancer under routine clinical practice conditions in Morocco. - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/42050453
Observational study in Morocco confirms trastuzumab biosimilar's cardiac safety and efficacy under routine clinical practice in HER2-positive breast cancer treatment.
The trastuzumab biosimilar demonstrated acceptable cardiac safety and comparable efficacy in Moroccan patients with HER2-positive breast cancer under routine clinical practice conditions.